Cargando…
Clinical and Safety Evaluation of Continuously Infused Ceftolozane/Tazobactam in the Outpatient Setting
BACKGROUND: Ceftolozane/tazobactam (C/T) is a novel cephalosporin/β-lactamase inhibitor currently dosed by 8-hour intervals to treat complicated and multidrug-resistant Pseudomonas aeruginosa infections in inpatients. This dosing strategy limits the ability to transition patients to outpatient antim...
Autores principales: | Jones, Bruce M, Huelfer, Kathryn, Bland, Christopher M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000837/ https://www.ncbi.nlm.nih.gov/pubmed/32042849 http://dx.doi.org/10.1093/ofid/ofaa014 |
Ejemplares similares
-
1926. Evaluation of Safety and Effectiveness of Continuous Infusion Ceftolozane/Tazobactam as Outpatient Parenteral Antimicrobial Therapy
por: Jones, Bruce M, et al.
Publicado: (2018) -
Microbiome Restoration by RBX2660 Does Not Preclude Recurrence of Multidrug-Resistant Urinary Tract Infection Following Subsequent Antibiotic Exposure: A Case Report
por: Keen, Eric C, et al.
Publicado: (2020) -
Nail Findings in Chikungunya Infection
por: Swaminathan, Priya, et al.
Publicado: (2020) -
Assessment of ceftolozane/tazobactam stability in elastomeric devices
and suitability for continuous infusion via outpatient parenteral antimicrobial
therapy
por: Jamieson, Conor, et al.
Publicado: (2021) -
Inference of Epistatic Effects Leading to Entrenchment and Drug Resistance in HIV-1 Protease
por: Flynn, William F., et al.
Publicado: (2017)